A hepatitis A antibody is a protein your immune system produces in response to the hepatitis A virus, either from an actual infection or from vaccination. When your doctor orders a hepatitis A antibody test, they’re looking for these proteins in your blood to determine whether you have a current infection, had one in the past, or are immune. The test is highly accurate, with both sensitivity and specificity above 99%.
Two Types of Hepatitis A Antibodies
Your body makes two distinct antibodies against hepatitis A, and each one tells a different story about your health.
IgM antibodies are the first responders. They appear early during an active infection and typically remain detectable for about three to six months. A positive IgM result points to a recent or current hepatitis A infection. This is the marker doctors use to diagnose acute hepatitis A.
IgG antibodies develop later and stick around for life. They show up after you’ve recovered from an infection or after you’ve been vaccinated. A positive IgG result (without IgM) means you’re immune to hepatitis A. Your body has already learned how to fight the virus, and you’re protected against future infections.
What “Total Anti-HAV” Means on Your Lab Report
Lab tests for hepatitis A antibodies come in two forms. A “total anti-HAV” test detects both IgM and IgG antibodies together. It tells you whether your body has ever encountered the virus or vaccine, but it can’t distinguish between a current infection and past immunity. If the total test comes back positive (or “reactive”), a separate IgM-specific test is usually needed to determine whether an active infection is present.
A non-reactive total anti-HAV result means you have no detectable antibodies. You haven’t been infected, you’re not currently infected, and you’re not immune. This is the result that typically prompts a recommendation for vaccination.
How the Antibody Timeline Works
After exposure to hepatitis A, symptoms usually take 15 to 50 days to appear. IgM antibodies become detectable around the time symptoms start, which is why testing is most useful once you’re actually feeling sick. The virus is contagious before symptoms appear, which makes outbreaks hard to contain.
IgM levels peak during the first month of illness, then gradually decline. IgG antibodies rise as IgM falls and remain in your bloodstream indefinitely. This transition from IgM to IgG is the hallmark of recovery and long-term immunity.
Vaccine-Induced Antibodies
The hepatitis A vaccine triggers the same IgG antibody response as a natural infection, just without making you sick. Protection builds quickly: 97% to 100% of children develop protective antibody levels within one month of the first dose. After the second dose, that number reaches 100%.
The protection lasts far longer than many people expect. In studies tracking adults who received two doses, more than 97% still had detectable antibodies 20 years later. Mathematical modeling suggests protection persists in at least 95% of vaccinated people at 30 years and 90% or more at 40 years. Children vaccinated before age two maintained antibody levels into their mid-teens, with models predicting at least 30 years of protection.
Even a single dose provides substantial protection. Antibody levels from one dose can persist for nearly 11 years, and if levels do drop, a booster shot triggers a strong immune response.
When Results Can Be Misleading
False positive IgM results, while uncommon, do occur. The most recognized causes involve autoimmune conditions and certain viral infections. Autoimmune hepatitis, for example, can produce cross-reacting antibodies that mimic a positive hepatitis A IgM result. Active Epstein-Barr virus infection (the virus behind mono) has also been linked to false positives.
This matters because a false positive IgM could lead someone to believe they have acute hepatitis A when the real cause of their liver inflammation is something else entirely. If your IgM result is positive but your symptoms or risk factors don’t fit the typical picture, additional testing can help sort out what’s really going on.
Why This Test Still Matters
Hepatitis A remains an active public health concern in the United States. Since late 2016, widespread outbreaks have spread through person-to-person contact, particularly among people who use drugs or are experiencing homelessness. The estimated number of new infections peaked around 2019 and has been declining since 2020, reaching about 4,500 cases in 2022. That represents a 32% drop from the 2017 baseline, though it still fell slightly short of national targets.
Antibody testing serves two purposes in this context. It identifies active infections during outbreaks so public health teams can respond, and it identifies people who lack immunity so they can be vaccinated before exposure occurs. Since hepatitis A has no chronic form and no specific treatment beyond supportive care, prevention through vaccination and early identification through antibody testing remain the primary tools for controlling the virus.